The combination treatment of Tecentriq (atezolizumab) and Avastain (bevacizumab) improved patient-reported outcomes and quality of life in a recent phase 3 study.
When compared to Nexavar (sorafenib) as a first-line treatment for patients with unresectable hepatocellular carcinoma (HCC), the combination of Tecentriq (atezolizumab) and Avastin (bevacizumab) produced better patient-reported outcomes in the recent phase 3 IMbrave150 trial, according to Dr. Peter Galle.
Galle, an oncologist at the Mainz University Medical Center in Germany, presented updated findings at the American Society of Clinical Oncology’s Gastrointestinal Cancers Symposium that not only showed an improved overall survival for patients on Tecentriq and Avastain, but also a better quality of life.
Galle sat down with CURE and discussed these patient-reported outcomes, their implications for future treatment, and why patient feedback is a vital part of any study.
TRANSCRIPTION
The data was consistent throughout the different scales assessed. And there was also an exploratory analysis specific for hepatocellular carcinoma patients assessing their symptoms. And all these symptoms were also delayed compared to sorafenib. They included fatigue, jaundice, pain and others.
The implication (of this research) is that we now have not only a treatment which is efficacious and is working in patients, but also well tolerated. This is a nice addition to efficacy that patients do not suffer too much from therapy. I think it's increasingly accepted that patient reported outcomes are relevant. Whatever you do to a patient, you need to hear the patient voice, in order to learn whether the impact on the tumor is not coming at too high a price.
Creating a Charity 8 Days After a Rare Cancer Diagnosis: Dying Defiantly Founder Shares His Story
December 8th 2022After Marshall Morris was diagnosed with a rare cancer and given only six months to live, he created a charity that empowers people with terminal illness and provides them with counseling and support.
Listen
Poor Liver Function Can Cause Side Effects, Drug Discontinuation in HCC
January 22nd 2024Patients with unresectable hepatocellular carcinoma and poor liver function were more likely to experience serious side effects leading to regorafenib treatment discontinuation, researchers have found.
Read More
Hepatitis Treatments Underutilized Among ‘Sickest’ With Liver Cancer
January 19th 2024Antiviral treatments play a crucial role in the survival of patients with either hepatitis B or C and liver cancer, but researchers have found that antiviral therapy is “severely underutilized” even among patients who undergo curative surgery.
Read More